SEC Company Response from Corbus Pharmaceuticals Holdings, (CRBP) — Mar 18, 2026
Corbus Pharmaceuticals Holdings, Inc.
Date: March 18, 2026 · CIK: 0001595097 · Accession: 0001193125-26-113993
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294217
Letter
Re: Corbus Pharmaceuticals Holdings, Inc. (the “Company”)
Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive Norwood, MA 02062 March 18, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Registration Statement on Form S-3 (File No. 333-294217) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:30 p.m., Eastern Time, on March 20, 2026, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. Please call Stephen Zapf of Lowenstein Sandler LLP at (973) 422-6708 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
CORBUS PHARMACEUTICALS HOLDINGS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive Norwood, MA 02062 March 18, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Corbus Pharmaceuticals Holdings, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-294217) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:30 p.m., Eastern Time, on March 20, 2026, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. Please call Stephen Zapf of Lowenstein Sandler LLP at (973) 422-6708 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, CORBUS PHARMACEUTICALS HOLDINGS, INC. By: /s/ Sean Moran Name: Sean Moran Title: Chief Financial Officer